DISTINCTION BETWEEN TRANSIENT HYPERGLYCEMIA AND EARLY INSULIN-DEPENDENT DIABETES-MELLITUS IN CHILDHOOD - A PROSPECTIVE-STUDY OF INCIDENCE AND PROGNOSTIC FACTORS

被引:41
作者
HERSKOWITZDUMONT, R
WOLFSDORF, JI
JACKSON, RA
EISENBARTH, GS
机构
[1] CHILDRENS HOSP MED CTR, BOSTON, MA 02115 USA
[2] HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA
关键词
D O I
10.1016/S0022-3476(05)81731-7
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
We prospectively studied 63 children with transient hyperglycemia to determine their risk of acquiring insulin-dependent diabetes mellitus (IDDM) and to evaluate the predictive value of immunologic markers of prediabetes and of the intravenous glucose tolerance test. Children with transient hyperglycemia were identified by a prospective systematic review of the laboratory reports of a large children's hospital and an office-based pediatric practice and by referral from pediatricians. Transient hyperglycemia occurred in 0.46% of children seen in the children's hospital and in 0.013% of children attending a pediatric office practice. Insulin-dependent diabetes mellitus developed within 18 months of identification in 32% of children in whom transient hyperglycemia was discovered in the absence of a serious illness, compared with 2.3% of children identified during a serious illness (relative risk, 13.9; 95% confidence interval, 1.56 to 123.5). Islet cell antibodies and competitive insulin autoantibodies each had a 100% positive predictive value for IDDM; the negative predictive value of islet cell antibodies and competitive insulin autoantibodies was 96% and 98%, respectively. The stimulated insulin release during an intravenous glucose tolerance test, adjusted for age, had the highest overall accuracy of prediction. All children less than 6 years of age with stimulated insulin release levels <85 pmol/L (12 muU/ml) subsequently had IDDM, as did an 11-year-old child whose stimulated insulin release level was below the lst percentile of 170 pmol/L (24 muU/ml). To date, no child whose stimulated insulin release level was above the 5th percentile has had IDDM. We conclude that when transient hyperglycemia occurs during a serious intercurrent illness, the risk of progression to IDDM is low. In contrast, one third of children in whom transient hyperglycemia is identified without a serious illness can be expected to have IDDM within 1 year. A combination of islet cell antibodies, competitive insulin autoantibodies, and stimulated insulin release levels during an intravenous glucose tolerance test can accurately distinguish children with prediabetes from those with presumed benign transient increases in plasma glucose concentrations.
引用
收藏
页码:347 / 354
页数:8
相关论文
共 21 条
[1]  
ALLEN H F, 1992, Pediatric Research, V31, p182A
[2]  
BECKER DJ, 1986, PEDIATRIC ADOLESCENT, V15, P61
[3]   IMMUNOLOGY AND DIABETES WORKSHOP - REPORT ON THE 3RD INTERNATIONAL (STAGE-3) WORKSHOP ON THE STANDARDIZATION OF CYTOPLASMIC ISLET CELL ANTIBODIES HELD IN NEW-YORK, NEW-YORK, OCTOBER 1987 [J].
BOITARD, C ;
BONIFACIO, E ;
BOTTAZZO, GF ;
GLEICHMANN, H ;
MOLENAAR, J .
DIABETOLOGIA, 1988, 31 (07) :451-452
[4]   PREDICTION OF THE COURSE OF PRE-TYPE-1 DIABETES [J].
CHASE, HP ;
GARG, SK ;
BUTLERSIMON, N ;
KLINGENSMITH, G ;
NORRIS, L ;
RUSKEY, CT ;
OBRIEN, D .
JOURNAL OF PEDIATRICS, 1991, 118 (06) :838-841
[5]   THE NATURAL-HISTORY OF TYPE-I DIABETES [J].
EISENBARTH, GS ;
CONNELLY, J ;
SOELDNER, JS .
DIABETES-METABOLISM REVIEWS, 1987, 3 (04) :873-891
[6]   DIFFERENTIAL SENSITIVITY TO BETA-CELL SECRETAGOGUES IN EARLY, TYPE-I DIABETES-MELLITUS [J].
GANDA, OP ;
SRIKANTA, S ;
BRINK, SJ ;
MORRIS, MA ;
GLEASON, RE ;
SOELDNER, JS ;
EISENBARTH, GS .
DIABETES, 1984, 33 (06) :516-521
[7]   TRIAD OF MARKERS FOR IDENTIFYING CHILDREN AT HIGH-RISK OF DEVELOPING INSULIN-DEPENDENT DIABETES-MELLITUS [J].
GINSBERGFELLNER, F ;
WITT, ME ;
FRANKLIN, BH ;
YAGIHASHI, S ;
TOGUCHI, Y ;
DOBERSEN, MJ ;
RUBINSTEIN, P ;
NOTKINS, AL .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1985, 254 (11) :1469-1472
[8]  
HARRIS M, 1979, DIABETES, V28, P1039
[9]  
HAYES EJ, 1981, CLIN CHEM, V27, P476
[10]  
HERSKOWITZ RD, 1988, DIABETES RES CLIN EX, V9, P161